A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer

Cadoo, KA; Grisham, RN; O'Cearbhaill, RE; Boucicaut, NN; Henson, M; Iasonos, A; Zhou, Q; Sarasohn, DM; Gallagher, J; Kravetz, S; Zamarin, D; Makker, V; Sabbatini, PJ; Tew, WP; Aghajanian, C; Konner, JA

Cadoo, KA (corresponding author), Mem Sloan Kettering Canc Ctr, 300 E66th St,13th Floor, New York, NY 10065 USA.

GYNECOLOGIC ONCOLOGY, 2020; 157 (1): 214

Abstract

Objective. We assessed the safety and maximum tolerated dose (MTD) of the poly ADP-ribose polymerase (PARP) inhibitor olaparib with intravenous (IV)/i......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索